Drug
Isatuximab clinical trials
Also written Sarclisa and SAR650984.
Keep track of what changes. Save the isatuximab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
70 studies that test it; most in 2021 (12); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 12 |
| 2022 | 12 |
| 2023 | 9 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 50
Sanofi (19) · Medical College of Wisconsin (3) · Massachusetts General Hospital (3) · University of Heidelberg Medical Center (3) · Canadian Myeloma Research Group (2) · M.D. Anderson Cancer Center (2) · UNC Lineberger Comprehensive Cancer Center (2) · Universitätsklinikum Hamburg-Eppendorf (2)
Often tested with
Tested in the same studies.
Dexamethasone (25) · Lenalidomide (13) · Bortezomib (12) · Carfilzomib (8) · Pomalidomide (7) · Cyclophosphamide (3) · Belantamab mafodotin (2) · Cemiplimab (2)
Studies
Open first, then newest update. How each study uses isatuximab is read from its arms, and is right about nine times in ten.
Testing it · 71
- Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple MyelomaRecruitingPhase 2University of UtahNCT06517017Written as Isatuximab
- Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering MyelomaRecruitingPhase 2University College, LondonNCT06762769Written as Isatuximab
- Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma PatientsRecruitingPhase 2M.D. Anderson Cancer CenterNCT05776979Written as Isatuximab
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From IsatuximabEnrolling by invitationPhase 2SanofiNCT05669989Written as Isatuximab intravenous (IV)
- D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMMRecruitingPhase 3Dana-Farber Cancer InstituteNCT07624513Written as Isatuximab
- Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma CellsNot yet recruitingPhase 2/3The Affiliated People's Hospital of Ningbo UniversityNCT07732712Written as Isatuximab
- Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaRecruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07714512Written as Isatuximab
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07652905Written as Isatuximab
- ELISA in Relapsed/Refractory MMRecruitingPhase 2Massachusetts General HospitalNCT06832865Written as Isatuximab SC
- Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM PatientsRecruitingPhase 2Canadian Myeloma Research GroupNCT05272826Written as Isatuximab
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1/2Natalie CallanderNCT07479979Written as Isatuximab
- Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic LeukemiaRecruitingPhase 2Goethe UniversityNCT06648889Written as Isatuximab
- Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple MyelomaRecruitingPhase 2University of Illinois at ChicagoNCT05344833Written as Isatuximab
- Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple MyelomaRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT05145400Written as Isatuximab
- Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingPhase 1/2Universitätsklinikum Hamburg-EppendorfNCT07600151Written as Isatuximab
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal InsufficiencyRecruitingPhase 2Medical College of WisconsinNCT04240054Written as Isatuximab
- Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruitingPhase 2Massachusetts General HospitalNCT05922501Written as Isatuximab
- Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous TherapyRecruitingPhase 2Intergroupe Francophone du MyelomeNCT05066607Written as Isatuximab
- Efficacy of the antiCD38 Monoclonal Antibody Isatuximab in the Treatment of PCRA by Major ABO Mismatch After Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT05559827Written as Isatuximab
- A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome InhibitorNot yet recruitingPhase 2Hellenic Society of HematologyNCT05298683Written as Isatuximab
See all 71 studies that test isatuximab →
Given in every arm · 20 — isatuximab is usual care beside what is tested
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolRecruitingPhase 1/2SanofiNCT04643002Written as Isatuximab
- Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed MyelomaNot yet recruitingPhase 1/2Dana-Farber Cancer InstituteNCT07601100Written as Isatuximab
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTRecruitingPhase 3AstraZenecaNCT07764978Written as Isatuximab
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Isatuximab
- NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomideRecruitingPhase 3PETHEMA FoundationNCT05558319Written as Isatuximab
- Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)RecruitingPhase 2PETHEMA FoundationNCT07045909Written as Isatuximab
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersRecruitingPhase 1/2Indapta Therapeutics, INC.NCT06119685Written as Isatuximab
- Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma PatientsRecruitingPhase 2/3University Hopsital Schleswig Holstein Campus LübeckNCT05665140Written as Isatuximab
- Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple MyelomaRecruitingPhase 2Karolinska InstitutetNCT04558931Written as Isatuximab
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingPhase 2SanofiNCT06356571Written as Isatuximab SC-OBDS
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingPhase 1/2GlaxoSmithKlineNCT04126200Written as Isatuximab
- Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).Active, not recruitingPhase 3Poitiers University HospitalNCT04751877Written as Isatuximab
- Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma PatientsCompletedPhase 3SanofiNCT03275285Written as isatuximab SAR650984
- Isatuximab in Lung Transplant RecipientsWithdrawnEarly Phase 1NYU Langone HealthNCT05862766Written as Isatuximab
- Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMMActive, not recruitingPhase 2Arbeitsgemeinschaft medikamentoese TumortherapieNCT04891809Written as Isatuximab-Irfc 20 MG/ML [Sarclisa]
- A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Active, not recruitingPhase 1/2CelgeneNCT03989414Written as Isatuximab
- Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological MalignanciesCompletedPhase 1/2SanofiNCT01084252Written as Isatuximab SAR650984
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaTerminatedPhase 1PfizerNCT03530683Written as Isatuximab
- Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) PatientsCompletedPhase 1/2SanofiNCT03194867Written as Isatuximab SAR650984
- Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced MalignanciesTerminatedPhase 1/2SanofiNCT03367819Written as Isatuximab SAR650984
As the comparator · 1 — what is tested is compared with isatuximab
Codes
What other systems call isatuximab · ClinicalTrials.gg INT000257
- MeSH (NLM) C000599209isatuximabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) R30772KCU0ISATUXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 2282018Confirmed FDA, Wikidata
- Wikidata Q20707906isatuximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C90578IsatuximabOne source FDA
- DrugBank DB14811One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599209 | isatuximab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | R30772KCU0 | ISATUXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2282018 | — | Confirmed FDA, Wikidata |
| Wikidata | Q20707906 | isatuximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C90578 | Isatuximab | One source FDA |
| DrugBank | DB14811 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.